The crystal structure of human angiogenin (reported in the preceding paper in this issue) reveals that the site that corresponds to the pyrimidine binding site of RNase A is obstructed by Gln-117. Mutation of this residue to Ala and Gly is here found to increase activity 11-to 18-fold and 21-to 30-fold, respectively, toward dinucleotide, polynucleotide, and cyclic nucleotide substrates, but without changing specificity.
slightly more active than each individual mutant. The present results demonstrate that Gin-117 impedes the ribonucleolytic activity of angiogenin, as predicted by x-ray crystallography. Moreover, they suggest that prior to or during catalysis angiogenin must undergo a conformational change to reorient the C-terminal segment that contains this residue, and that a similar reorganization is required for the mutants as well. This view is supported by molecular modeling of an angiogeninuridine vanadate complex. These in vitro findings have implications for the angiogenic activity of angiogenin in vivo.
Two unique properties distinguish angiogenin (Ang) from all other members of the pancreatic RNase superfamily (1): potent in vivo angiogenic activity (2) and extremely weak enzymatic activity toward standard RNase substrates (3) . Despite its seeming inefficiency, this ribonucleolytic activity is nonetheless crucial for angiogenicity: mutations within or near the enzymatic active site markedly decrease angiogenin's capacity to induce blood-vessel formation (4) (5) (6) (7) . Ang also contains another region, equally essential for angiogenic activity, that is thought to constitute a cell-surface receptor binding site (8, 9) .
Previous investigations of the structural basis for the characteristic activities of human Ang have been guided in large part by its homology with RNase A. The catalytic site of Ang, like that of RNase (10) (11) (12) (13) , has been thought to contain various subsites, including a P1 site at which phosphodiester bond cleavage occurs, a B1 site for binding the pyrimidine moiety of the 3' nucleoside, and a B2 site for binding the base of the 5' nucleoside. Homology considerations suggested that two of these subsites, P1 and B1, would be quite similar in the two proteins since all of the known RNase participants-i.e., His-12, Lys-41, His-119, and Gln-11 (P1), and Thr-45 and Ser-123 (Bl)-are conserved in Ang as His-13, Lys-40, His-114, Gln-12, Thr-44, and Ser-118, respectively. Indeed, results of Ang mutagenesis are consistent both with this definition of the P1 site (4, 5) and with the proposed role of Thr-44 in the B1 site (7) . However, other findings indicate that some active-site residues, although conserved in the amino acid sequence, may not be functionally equivalent in the two proteins. For example, the failure of Ser-118 replacements to alter specificity (7) shows that this residue, unlike Ser-123 in RNase (14) , is not involved in pyrimidine recognition. More strikingly, a number of mutations of Asp-116 in Ang increase enzymatic activity substantially (15, 16) , whereas substitutions of the corresponding RNase residue Asp-121 decrease activity (17) .
The crystal structure of Ang described in the preceding paper (18) reveals possible explanations for both the low enzymatic activity of Ang and the unexpected effects of mutagenesis. The conformation of the C-terminal region of Ang differs markedly from that of RNase and, as a result, the site predicted to constitute the B1 pocket for pyrimidine binding is occupied by Gln-117. The neighboring architecture is also distinct from that in RNase: Asp-116 and Ser-118 are shifted considerably from the positions of their counterparts in RNase, and several residues occupy an adjacent region that is accessible in RNase. These observations raise a number of critical questions, among which are (i) does the active site conformation seen in the crystalline state also exist in solution and, if so, (ii) does the B1 site open up during the normal catalytic pathway of Ang? The results of the present mutagenesis and molecular modeling study provide strong evidence that Gln-117 indeed obstructs the active site of the native enzyme and that reorientation ofthe C-terminal region may be an obligatory prelude to catalysis.
MATERIALS AND METHODS
Human Ang was obtained from a recombinant expression system in Escherichia coli (19) . Sources of other materials have been listed previously (3, 19, 20) .
Site-Directed Mutagenesis. PCR was used to obtain genes encoding mutant angiogenins. The template for PCR was the expression plasmid pAng3 (6), which contains a synthetic Ang gene. The segment amplified corresponds to Ang residues 58-123 and contains unique BstEII and Stu I restriction sites near the 5' and 3' ends, respectively. The 5' amplification primer in all cases was 5'-GAAAACAAAAACGG-TAACCCGC-3'. The 3' primers used to introduce the mutations were 5'-TTAAGGCCTTCGGAAGATAGAC CATCTAGATGGAC-3' (Gln-117 -* Ala mutant, Q117A), 5'-TTAAGGCCTTCGGAAGATAGACCCATCTAGATG-GAC-3' (Q117G), and 5'-TTAAGGCCTTCGGAAGATA-GACGCAGCTAGATGGACTGG-3' (D116A/Q117A). PCR products were purified with a Magic PCR Preps kit (Promega), digested with BstEII and Stu I, and ligated into pAng3 that had been cleaved with the same enzymes. E. coli W3110 cells were then transformed with the resultant plasmids. The PCR-derived region of each plasmid was seAbbreviations: UVan, uridine vanadate; Ang, angiogenin.
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Preparation and Structural Characterization of Ang Mutants. Mutant proteins were expressed in E. coli, purified to homogeneity, and subjected to tryptic peptide mapping as described (1, 6, 9) . Protein concentrations were determined by amino acid analysis (21) .
Assays. Ribonucleolytic activity toward tRNA was measured as described (22) . Values for kcat/Km with dinucleotide and cyclic nucleotide substrates were determined by an HPLC method. Incubations were performed at 25°C in 0.2 M 2-(N-morpholino)ethanesulfonic acid (pH 5.9), with RNasefree bovine serum albumin included at 0.1 mg/ml in those reaction mixtures that contained <0.3 ,uM enzyme. After various times, substrate and products in dinucleotide assays were quantitated by C18 HPLC as described (3, 20) (24) was used to modify the native Ang structure to accommodate the mutations of Gln-117 to Ala and Gly. The mutant protein models were then subjected to conjugate gradient energy minimization using -the XPLOR program (25) until convergence. All minimizations were done in the absence of solvent. Restricted conformational searches-(i) rotations about the glycosidic bond and (ii) changes in the ribose conformationwere performed with FRODO (24) using the structural descriptions provided in ref. 26 .
RESULTS
Production and Structural Characterization of Ang Mutants Q117A and Q117G. Q117A and Q117G were expressed in E. coli by established procedures (6, 19) in yields of -0.3 mg/liter of culture. Their retention times during Mono S and C18 HPLC are indistinguishable from those of native Ang. [Enzyme], nM 150 The amino acid compositions of both mutants are in agreement with the proposed structures. C18 HPLC elution profiles of tryptic digests are identical to that obtained with Ang (1) except with respect to peptide T-11, which contains the mutation site. The Q117G and Q117A T-11 peptides are eluted 1 and 2 min, respectively, after the native T-11, consistent with the expected substitutions.
Ribonucleolytic Activity of Q117A and Q117G. The activities of Q117A and Q117G toward tRNA were determined by measuring the rate of formation of perchloric acid-soluble products. Both mutants are significantly more active in this assay than is Ang: Q117A by 18-fold and Q117G by 30-fold (Fig. 1) . Changes in specificity were assessed from kcat/Km values obtained with cytidylyl(3' ,5')adenosine (CpA), cytidylyl(3',5')guanosine (CpG), uridylyl(3',5')adenosine (UpA), cytidine cyclic 2',3'-phosphate (C > p), and uridine cyclic 2',3'-phosphate (U > p) as substrates. Under the conditions employed,$ Ang exhibits an -20-fold preference for C vs. U as the nucleotide contributing its 3'-phosphate to the scissile bond and a 3-fold preference for A vs. G on the 5' side of the cleavage site. These specificities are not altered appreciably by either mutation: the activities of Q117G toward all five substrates are increased by similar factors (21-to 30-fold), as are those of Q117A with the three substrates tested (range, 11-to 14-fold) ( Table 1) . The kcat/Km values for Ang-catalyzed hydrolysis ofC > p and U > p, which have not been reported previously, are lower by only a factor of -25 than those for the best CpN and UpN substrates, respectively. In contrast, with RNase A there is a 650-fold difference between corresponding cyclic nucleotide and dinucleotide substrates.
The effects of the Gln --Gly substitution on the individual kinetic parameters kcat and Km were examined with CpA as substrate. Previous efforts to determine these parameters for Ang had been unsuccessful owing to the anomalous shapes of the kinetic plots obtained (7) . However, data acquired under the modified assay conditions used in the present study yielded Lineweaver-Burk plots that were linear over at least a 3-fold range of concentrations spanning the Km (Fig. 2) . These plots show that the mutation decreases Km by a factor of about 5 (from 62 to 13 mM), while increasing kcat by 6 from D116A/Q117A is eluted 4 min after native T-11 during C18 HPLC.
The activity of D116A/Q117A toward tRNA is 25-fold greater than that of Ang-i.e., only slightly higher than that of each single-residue mutant. Activities toward dinucleotides are also increased considerably compared to those seen with Ang (Table 1) , but in all instances they are no more than 2-fold higher than those measured for Q117A. Specificity at position N of NpN' dinucleotides is virtually unchanged, but the preference for A vs. G at position N' is somewhat altered, as was observed for several ofthe Asp-116 mutants (16) .
Modeling of Structural Effects of Gln-117 Mutations. The structural basis for the improvements in activity and pyrimidine binding associated with the Ala and Gly mutations at Gln-117 was investigated by molecular modeling. The nucleotide analog uridine vanadate (UVan) was positioned at the Ang active site by superimposing the crystal structures of human Ang (18) and the RNase A-UVan complex (28) . As reported previously (18) , the orientations of the catalytic residues His-13, Lys-40, and His-114 in the resultant AngUVan structure are essentially the same as for the corresponding amino acids in RNase A, but the positions of Gln-117 and the uracil ring are incompatible (Fig. 3 Upper). Since the a and f carbons of Gln-117 are only 1.2 and 0.6 A, respectively, from the pyrimidine in this model, a simple shortening of the side chain to Gly or Ala would likely be insufficient to allow uridine binding unless accompanied by substantial movements in the other C-terminal residues. The possibility that such movements could occur was examined by performing energy minimization on the modified structures. Although the backbone and several side chains in the active-site region of these calculated structures are shifted somewhat with respect to native Ang, the distances separating Gly-117 (Fig. 3 Lower) and Ala-117 from uracil remain too small (1.1 and 0.7 A, respectively) to allow access of the substrate to this site. In the RNase A-UVan crystal structure, the conformation at the glycosidic bond of UVan is anti and the ribose ring pucker is a slightly distorted form ofC(3')endo (28) . Modeling was used to examine whether alteration of these conformations might permit binding of UVan to the native Ang structure observed or to those calculated for the mutants. The results indicate that rotations about the glycosidic bond do not alleviate the steric problems in any of the structures, nor do changes of the envelope conformation to the C(2')endo, C(3')exo, or C(2')exo forms, even if small movements are allowed for the portion of UVan that interacts with the catalytic histidines and lysine in RNase A.
DISCUSSION
The C-terminal segment ofRNase A provides His-119, one of the residues essential for catalysis, as well as other amino acids that play less critical roles (e.g., Asp-121 and Ser-123) (11, 12, 29) . In Ang, most of this segment, including the three residues cited, is conserved, and yet it is not functionally equivalent to its RNase counterpart (7, 15, 16, 30) . This was demonstrated dramatically by replacing Asp-116 in Ang with Asn, Glu, and Ala, which enhanced activity 8-, 9-, and 15-fold, respectively (15, 16) , whereas the same substitutions (of Asp-121) in RNase decreased activity by factors of between 2 and 40, depending on the substrate (17, 31, 32) .
X-ray crystallography has revealed the actual magnitude of the structural dissimilarity in the C-terminal segments of Ang and RNase A [preceding paper (18) ]. Beginning with residue 116, this region of the polypeptide chain of Ang diverges markedly from that in RNase: it forms a 310-helix oriented in one direction whereas in RNase it is part of an extended (-strand that begins several residues earlier and is oriented in another. The most striking consequence of this difference is that in Ang the site that is spatially analogous to the pyrimidine binding pocket B1 in RNase is occupied by Gln-117 (see Fig. 3 ). In fact, this residue forms two hydrogen bonds with Thr-44, much as the pyrimidine does with Thr-45 in RNase. In addition, the side chain of Asp-116 is shifted about 3 A from the position of Asp-121 in RNase, so that it hydrogen bonds not to the His-114 imidazole as in RNase but to the Ser-118 3-hydroxyl group. This serine in turn is located -7 A from the position of Ser-123 in RNase and is directed away from, rather than toward, the site corresponding to B1. Additional hydrogen bonds connecting various main-chain atoms (Phe-120 to Gln-117 and Arg-122, Ser-118 to Arg-121) also serve to stabilize the C-terminal structure.
Although the position of Gln-117 would seem to be incompatible with RNA binding, nonetheless, Ang is enzymatically active: in the assay systems tested thus far it catalyzes RNA cleavage, albeit only slowly. There are three potential explanations for this apparent discrepancy: (i) the impediment to binding in the crystalline state is not present when Ang is in solution, (ii) the substrate adopts a conformation different from that observed in RNase-inhibitor complexes which allows an alternative mode of binding of the pyrimidine ring, and (iii) prior to or during catalysis Ang can acquire a conformation in which Gln-117 does not obstruct the B1 site. The present study has examined these alternatives by sitespecific mutagenesis and molecular modeling. Gln-117 was replaced by Ala and Gly, selected because of their small size and lack of hydrogen-bonding capacity. Ala is the corresponding residue in RNase.
Mutations of Gln-117 increase enzymatic activity 11-to 30-fold, a clear demonstration that this residue indeed contributes to the suppression of the activity of Ang in solution. Moreover, the improved binding of 2'-CMP to Q117G, together with the unchanged binding of 5'-AMP, is totally consistent with the presence of Gln-117 at the B1 site and indicates that this structural feature of Ang seen in the crystal also exists in solution.
Several lines of evidence, taken together, tend to militate against the possibility that the substrate assumes an alternative conformation that allows binding and catalysis to occur and instead support the contention that it is Ang that undergoes the change in conformation. The specificity changes accompanying mutations of Thr-44 (7) suggest that this residue participates directly in pyrimidine recognition. This would ohly be possible if Thr-44 and Gln-117 were no longer within`? ydrogen-bonding distance of each other and far enough apart to accommodate pyrimidine binding. The specificities of Ang, Q117A, and Q117G are all similar, which implies that the pyrimidine moiety of the substrate interacts with all of these proteins in much the same manner. Thus, if the pyrimidine were to bind to Ang outside the obstructed site, this would also be the case with the mutants. It would then be difficult to explain why the mutations markedly enhance activity and pyrimidine binding. If, however, the binding site becomes available only on reorientation of the Ang structure, the mutations could readily facilitate this process, since they remove the Gln-117/Thr-44 hydrogen bonds that help stabilize the native (i.e., inactive) conformation. The somewhat higher activity of Q117G compared with Q117A might reflect a greater freedom of movement of the polypeptide backbone when glycine is at this position. The increased activities of Asp-116 mutants can also be interpreted in terms of their effect on the structure of Ang: such mutations may similarly open the B1 site by abolishing or weakening the Asp-116/Ser-118 hydrogen bond and thereby disrupting the Gln-117/Thr-44 interaction. Since mutation of either Asp-116 or Gln-117 brings about the same effect, it is not unreasonable that simultaneous mutations of both would be only slightly additive (Table 1) .
The molecular modeling results are also entirely in accord with the proposed requirement that Ang undergo a conformational change. For one, they predict that UVan binding to the native Ang structure would still be sterically impossible even if the inhibitor structure were altered either by rotating the uracil moiety or by changing the pucker of the ribose ring from (3')endo to any of the three major alternatives. Further, the Q117A and Q117G models (Fig. 3 ) generated by energy minimization are also unable to accommodate any of the UVan structures. This supports the experimentally based conclusion that a reorientation of the C-terminal region is necessary for substrate to bind properly to the mutants as well as to the native protein.
The structural rearrangement of Ang may occur before or after substrate binding as indicated: 5 E ± E* a E*S --E* + P s E ;a ES; ± E*S-*E* + P. Proc. Natl. Acad. Sci. USA 91 (1994) mutagenesis results cannot distinguish between these two mechanisms (or a third in which S can bind to either E or E*), they place constraints on each of them. If scheme I applies, the altered kinetic properties of Q117G cannot be solely due to a perturbation of the equilibrium between E and E*: such an effect would influence only Km whereas, in fact, both Km and kcat are changed (Fig. 2) . Hence, the mutation must increase activity in some way that can also affect kcat.-e.g., by improving the catalytic capacity ofthe E* form. In scheme H, both Km and kcat could be altered by a change in the open/closed (i.e., ES/E*S) equilibrium, although other factors may be involved as well. One possible molecular mechanism by which ES might be converted to E*S in this scheme can be ruled out: binding of the substrate 5'-nucleotide at the B2 site of Ang is not required to induce the open conformation, since cyclic 2',3'-nucleotides, which lack a B2-binding component, are also cleaved.
If Ang is indeed capable of undergoing the conformational change inferred from the present studies of in vitro catalysis, this could have important implications for its biological mode ofaction. As noted above, the ribonucleolytic activity ofAng is essential to its angiogenicity. Thus, Ang may be a latent enzyme that is subject to activation in vivo by an appropriate ligand. Its subsequent action on a specific substrate at its target site could then initiate the process of blood-vessel formation. One attractive candidate for such an effector would be the putative cell-surface receptor that mediates the angiogenic activity of Ang (8, 9) . Although the Ang amino acid residues thus far identified as important for receptor binding are not involved directly in enzymatic activity (6, 8, 9) , some are quite close to the likely B2 site. It is therefore plausible that interaction with the receptor could induce changes in the ribonucleolytic site. An alternative possibility is that activation occurs within the nucleus, since immunofluorescence studies suggest that Ang is targeted to and functions within the nucleolus (33) . Finally, it should be noted that the magnitude of the activation of Ang in vivo may be substantially greater than the 30-fold effect achieved by replacing Gln-117 with Gly, since, as discussed above, a conformational change appears to remain an obligate part of the catalytic pathway even for the mutant protein.
